Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Kidney International

• Publication date

  2002-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1523-1755.2002.00474.XPMID 12110039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• When should we start erythropoietin therapy?

  2001cited by this paper
• Small molecule mimics of hematopoietic growth factors: improving on Mother Nature?

  2001cited by this paper
• Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain

  2001cited by this paper
• Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats

  2001cited by this paper
• Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.

  2001cited by this paper
• Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor.

  2001cited by this paper
• Neocytolysis on Descent from Altitude: A Newly Recognized Mechanism for the Control of Red Cell Mass

  2001cited by this paper
• Development and characterization of novel erythropoiesis stimulating protein (NESP)

  2001cited by this paper
• The distal region and receptor tyrosines of the Epo receptor are non‐essential for in vivo erythropoiesis

  2001cited by this paper
• Impact of hematocrit on morbidity and mortality.

  2000cited by this paper
• European best practice guidelines 9-13: anaemia management.

  2000cited by this paper
• The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group.

  2000cited by this paper
• Gene Electrotransfer Results in a High-Level Transduction of Rat Skeletal Muscle and Corrects Anemia of Renal Failure

  2000cited by this paper
• Novel erythropoiesis stimulating protein.

  2000cited by this paper
• Erythropoietin mimetic peptides and the future.

  2000cited by this paper
• The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomized controlled multicentre trial

  2000cited by this paper
• Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer

  1999cited by this paper
• Mimicry of erythropoietin by a nonpeptide molecule.

  1999cited by this paper
• Subcutaneous treatment with recombinant human erythropoietin--the influence of injection frequency and skin-fold thickness.

  1999cited by this paper
• Erythropoietin receptor activation by a ligand-induced conformation change.

  1999cited by this paper
• Mechanism of erythropoietin-induced hypertension.

  1999cited by this paper
• Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

  1999cited by this paper
• Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells).

  1999cited by this paper
• Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.

  1999cited by this paper
• Prostaglandin E1 reduces the risk of delayed graft function after cadaveric renal transplantation.

  1999cited by this paper
• Neocytolysis contributes to the anemia of renal disease.

  1999cited by this paper
• Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site.

  1999cited by this paper
• Erythropoietin deficiency in hyporeninemia.

  1999cited by this paper
• Hematocrit level and associated mortality in hemodialysis patients.

  1999cited by this paper
• Efficiency of signalling through cytokine receptors depends critically on receptor orientation

  1998cited by this paper
• Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1.

  1998cited by this paper
• A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns].

  1998cited by this paper
• SUBCUTANEOUS COMPARED WITH INTRAVENOUS EPOETIN IN PATIENTS RECEIVING HEMODIALYSIS

  1998cited by this paper
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper
• Physiology and function of the erythropoietin receptor

  1998cited by this paper
• Anemia in predialysis chronic renal failure: what are we treating?

  1998cited by this paper
• Isolation of Erythropoietin Receptor Agonist Peptides Using Evolved Phage Libraries

  1998cited by this paper
• Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.

  1998cited by this paper
• Mapping of the active site of recombinant human erythropoietin.

  1997cited by this paper
• Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.

  1997cited by this paper
• NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative.

  1997cited by this paper
• LOCALIZATION OF ERYTHROPOIETIN GENE EXPRESSION IN PROXIMAL RENAL TUBULAR CELLS DETECTED BY DIGOXIGENIN‐LABELLED OLIGONUCLEOTIDE PROBES

  1996cited by this paper
• Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin

  1996cited by this paper
• Identification of a Critical Ligand Binding Determinant of the Human Erythropoietin Receptor

  1996cited by this paper
• In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.

  1996cited by this paper
• Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention.

  1996cited by this paper
• The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers.

  1995cited by this paper
• A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation.

  1995cited by this paper
• Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin.

  1995cited by this paper
• Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.

  1995cited by this paper
• Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients.

  1995cited by this paper
• Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia.

  1994cited by this paper
• Structure, function, and activation of the erythropoietin receptor.

  1993cited by this paper
• Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.

  1993cited by this paper
• Identification of the renal erythropoietin-producing cells using transgenic mice.

  1993cited by this paper
• Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.

  1992cited by this paper
• Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.

  1992cited by this paper
• The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

  1992cited by this paper
• Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice.

  1991cited by this paper
• Erythropoietin.

  1991cited by this paper
• Erythropoietin.

  1991cited by this paper
• Erythropoietin production in kidney tubular cells

  1990cited by this paper
• Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients.

  1990cited by this paper
• The role of carbohydrate in recombinant human erythropoietin.

  1990cited by this paper
• Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells.

  1990cited by this paper
• Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.

  1990cited by this paper
• Variations of recombinant human erythropoietin application in hemodialysis patients.

  1990cited by this paper
• The in vivo metabolism of recombinant human erythropoietin in the rat.

  1989cited by this paper
• Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure.

  1989cited by this paper
• Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.

  1989cited by this paper
• Survival of recombinant erythropoietin in the circulation: the role of carbohydrates.

  1989cited by this paper
• Comparative Pharmacokinetics of Recombinant Erythropoietin Administered by the Intravenous, Subcutaneous, and Intraperitoneal Routes in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients

  1989cited by this paper
• Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function.

  1988cited by this paper
• Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells.

  1988cited by this paper
• Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization.

  1988cited by this paper
• Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.

  1988cited by this paper
• Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells.

  1987cited by this paper
• Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA.

  1987cited by this paper
• L-triiodothyronine augments erythropoietic growth factor release from peripheral blood and bone marrow leukocytes.

  1986cited by this paper
• Structural characterization of human erythropoietin.

  1986cited by this paper
• The role of carbohydrate in erythropoietin action.

  1985cited by this paper
• Some chemical properties of human erythropoietin.

  1985cited by this paper

• Anemia of Chronic Kidney Disease in India: Consensus Guidelines of Indian Society of Nephrology

  2025cites this paper
• Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha

  2024influential citation
• A Cost-effective Purification Process for Erythropoietin Biosimilar through Downstream Process Engineering

  2023cites this paper
• Satisfying QTPP of Erythropoietin Biosimilar by QbD through DoE-Derived Downstream Process Engineering

  2023cites this paper
• Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP®

  2018cites this paper
• Targeted therapy and its availability in Serbia

  2014cites this paper
• Induction of eryptosis by uremic toxins

  2013cites this paper
• The impact of anemia on renal recovery and survival in acute kidney injury.

  2013cites this paper
• Peptide and Protein Derivatives

  2012cites this paper
• Etude des mécanismes cellulaires et moléculaires de l'inhibition de l'érythropoïèse par la cytokine pro-inflammatoire Tumor necrosis factor (TNF)-alpha

  2011cites this paper
• Erythropoietin, erythropoiesis and beyond.

  2011cites this paper
• Renal anemia: a nephrologist's view.

  2011cites this paper
• A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.

  2010cites this paper
• A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.

  2009influential citation
• Pathophysiology of anemia and erythrocytosis.

  2007cites this paper
• Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.

  2007cites this paper
• High expression level of recombinant human erythropoietin in the milk of non-transgenic goats.

  2006cites this paper
• The role of SHIP in hematopoiesis

  2005cites this paper
• Erythropoietin and the developing brain

  2004cites this paper
• Perioperative management of patients with chronic kidney disease or ESRD.

  2004cites this paper
• The cellular biology of erythropoietin receptors.

  2003cites this paper
• EPO's Alter Ego: Erythropoietin Has Multiple Actions

  2002cites this paper